Cargando…
Identification and functional analysis of novel oncogene DDX60L in pancreatic ductal adenocarcinoma
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer. Approximately 80% of patients initially diagnosed with locally advanced or metastatic disease survive only 4–11 months after diagnosis. Tremendous efforts have been made toward understanding the biology of PDAC. RESULTS: In this...
Autores principales: | Wu, Hongjin, Tian, Weiwei, Tai, Xiang, Li, Xuanpeng, Li, Ziwei, Shui, Jing, Yu, Juehua, Wang, Zhihua, Zhu, Xiaosong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600871/ https://www.ncbi.nlm.nih.gov/pubmed/34789165 http://dx.doi.org/10.1186/s12864-021-08137-5 |
Ejemplares similares
-
The Clinical and Pathological Significance of Nectin-2 and DDX3 Expression in Pancreatic Ductal Adenocarcinomas
por: Liang, Shan, et al.
Publicado: (2015) -
RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma
por: Tu, Qiu, et al.
Publicado: (2022) -
CCAT2 is an oncogenic long non-coding RNA in pancreatic ductal adenocarcinoma
por: Cai, Yi, et al.
Publicado: (2018) -
Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma
por: Venkat, Swati, et al.
Publicado: (2020) -
Identification of FEZ2 as a potential oncogene in pancreatic ductal adenocarcinoma
por: Yang, Chaozhi, et al.
Publicado: (2022)